Govt Invites Proposals Under Rs 50 Billion Pharma-MedTech Scheme

03 Oct 2025 CW Team

Revised guidelines have been issued to enhance the scheme’s effectiveness. For early-stage projects, MSMEs and startups may seek support of up to Rs 50 million for projects costing up to Rs 900 million. For later-stage projects, companies, MSMEs and startups may apply for assistance up to Rs 10 billion for projects valued at Rs 28.5 billion. Early-stage projects will receive 100 per cent support up to Rs 10 million, and 50 per cent beyond that, capped at Rs 50 million. Later-stage projects will receive 35 per cent support, capped at Rs 10 billion.

In Strategic Priority Innovation (SPI) areas—such as rare diseases, antimicrobial resistance, vaccine-preventable illnesses, tropical vector-borne diseases and pandemic pathogens—later-stage projects may receive 50 per cent assistance, capped at Rs 10 billion.

The scheme also incentivises industry, MSMEs and startups to collaborate with leading academic and government research institutions, offering preferential selection for up to nine early- and late-stage projects involving significant partnerships. Assistance may also be used for in-licensing research outputs from such institutions, linking academic strengths with industry’s capacity to scale technologies to market.

Institutional enablers will be strengthened through Centres of Excellence at seven NIPERs, acting as advanced research hubs. The NIPER Academia-Industry Coordination Committee will further enhance collaboration, while a digital Pharma-MedTech Innovation Exchange will connect innovators with investors, mentors and global opportunities.

The fully digital application process opened on 1 October 2025 via the PRIP portal. By attracting both domestic and international participation, the scheme aims to accelerate affordable, high-quality healthcare solutions, strengthen India’s public health resilience and position the country as a global leader in pharmaceutical and MedTech innovation.

The Department of Pharmaceuticals has opened applications for research and innovation projects under its Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, a landmark initiative aimed at transforming India into a globally competitive, innovation-led hub. With an approved outlay of Rs 50 billion, the scheme is expected to support around 300 projects, catalysing total R&D investment of about Rs 110 billion in new medicines, complex generics, biosimilars and novel medical devices.Revised guidelines have been issued to enhance the scheme’s effectiveness. For early-stage projects, MSMEs and startups may seek support of up to Rs 50 million for projects costing up to Rs 900 million. For later-stage projects, companies, MSMEs and startups may apply for assistance up to Rs 10 billion for projects valued at Rs 28.5 billion. Early-stage projects will receive 100 per cent support up to Rs 10 million, and 50 per cent beyond that, capped at Rs 50 million. Later-stage projects will receive 35 per cent support, capped at Rs 10 billion.In Strategic Priority Innovation (SPI) areas—such as rare diseases, antimicrobial resistance, vaccine-preventable illnesses, tropical vector-borne diseases and pandemic pathogens—later-stage projects may receive 50 per cent assistance, capped at Rs 10 billion.The scheme also incentivises industry, MSMEs and startups to collaborate with leading academic and government research institutions, offering preferential selection for up to nine early- and late-stage projects involving significant partnerships. Assistance may also be used for in-licensing research outputs from such institutions, linking academic strengths with industry’s capacity to scale technologies to market.Institutional enablers will be strengthened through Centres of Excellence at seven NIPERs, acting as advanced research hubs. The NIPER Academia-Industry Coordination Committee will further enhance collaboration, while a digital Pharma-MedTech Innovation Exchange will connect innovators with investors, mentors and global opportunities.The fully digital application process opened on 1 October 2025 via the PRIP portal. By attracting both domestic and international participation, the scheme aims to accelerate affordable, high-quality healthcare solutions, strengthen India’s public health resilience and position the country as a global leader in pharmaceutical and MedTech innovation.

Infrastructure Transport

06 Feb 2026

Lucknow Metro East-West Corridor Consultancy Contract Awarded

The Uttar Pradesh Metro Rail Corporation has awarded the first construction-related consultancy contract for the Lucknow Metro East West Corridor to a joint venture of AYESA Ingenieria Arquitectura SAU and AYESA India Pvt Ltd. The firm was declared the lowest bidder for the Detailed Design Consultant contract for Lucknow Metro Line-2 under Phase 1B and the contract was recommended following the financial bid. The contract is valued at Rs 159.0 million (mn), covering design services for the corridor. Lucknow Metro Line-2 envisages the construction of an 11.165 kilometre corridor connecting Cha..

Infrastructure Urban

06 Feb 2026

Div Com Kashmir Urges Fast Tracking Of Jhelum Water Transport Project

The Divisional Commissioner of Kashmir has called for the fast-tracking of the Jhelum water transport project, urging district administrations and relevant agencies to accelerate planning and clearances. In a meeting convened at the divisional headquarters, the commissioner instructed officials from irrigation, public health engineering and municipal departments to prioritise the project and coordinate survey and design work. The directive emphasised removal of administrative bottlenecks and close monitoring to ensure timely mobilisation of resources and contractors. Officials were told to in..

Infrastructure Urban

06 Feb 2026

Interarch Reports Strong Q3 And Nine Month Results

Interarch Building Solutions Limited reported unaudited results for the third quarter and nine months ended 31 December 2025, recording strong revenue growth driven by execution and a robust order book. Net revenue for the third quarter rose by 43.7 per cent to Rs 5.225 billion (bn), compared with Rs 3.636 bn a year earlier, reflecting heightened demand in pre-engineered building projects. The company’s total order book as at 31 January 2026 stood at Rs 16.85 bn, supporting near-term visibility. EBITDA excluding other income for the quarter increased by 43.2 per cent to Rs 503 million (mn),..